{
    "clinical_study": {
        "@rank": "111163", 
        "brief_summary": {
            "textblock": "To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir."
        }, 
        "brief_title": "The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Patients may receive oral acyclovir and may continue prophylactic treatment for PCP,\n             fungal infection, MAC and toxoplasmosis.\n\n          -  Topical treatment and intralesional chemotherapy will be allowed for lesions which\n             will not be used as indicator or biopsy lesions.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n        Localized radiotherapy will be allowed for lesions which will not be used as indicator or\n        biopsy lesions.\n\n        Patients must have:\n\n          -  Documentation of a positive ELISA test for HIV with a confirmatory test.\n\n          -  Biopsy proven, cutaneous or oropharyngeal Kaposi's sarcoma.\n\n          -  Vital signs, physical examination and laboratory assessments that exhibit no evidence\n             of an acute illness.\n\n          -  Patients must agree to report all current medications to the primary investigator and\n             obtain prior permission to use them when feasible.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Evidence of pulmonary Kaposi's sarcoma.\n\n          -  Positive urine screen for recreational drugs.\n\n          -  Current participation in another antiviral research study.\n\n          -  Investigator anticipates poor patient compliance with the protocol.\n\n          -  Patient has any condition that, in the investigator's opinion, may obscure the proper\n             observation of the safety or activity of ritonavir.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral therapy.\n\n          -  Protease inhibitor therapy.\n\n          -  Antiviral agent (e.g., oral ganciclovir or Foscarnet) or prophylactic medication for\n             an AIDS defining illness which the patient cannot be removed from.\n\n          -  Chemotherapy for Kaposi's sarcoma.\n\n          -  Treatment with any medications that may interact with ritonavir.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        Radiotherapy for Kaposi's sarcoma.\n\n        Patients with any of the following prior conditions are excluded:\n\n          -  History of psychiatric illness which is currently medically significant.\n\n          -  History of pancreatitis.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  All antiretroviral therapy within 2 weeks prior to the start of the treatment phase\n             of the study.\n\n          -  Systemic chemotherapy of interferon within 30 days prior to study entry.\n\n          -  Previous treatment with a protease inhibitor.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002366", 
            "org_study_id": "245C", 
            "secondary_id": "M95-320"
        }, 
        "intervention": {
            "intervention_name": "Ritonavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Ritonavir"
            ]
        }, 
        "keyword": [
            "Skin Neoplasms", 
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "HIV Protease Inhibitors", 
            "Ritonavir"
        ], 
        "lastchanged_date": "February 19, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia"
                    }, 
                    "name": "Saint Vincent's Hosp Med Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia"
                    }, 
                    "name": "Prince Henry's Hosp / Med Oncology"
                }
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "official_title": "A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "citation": "Carr A, Milliken S, Lewis C, Mitsuyasu R, Miles S, Newell M, Cooper DA. A pilot phase II safety and activity study of ritonavir in the treatment of HIV-associated cutaneous Kaposi's sarcoma. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:194 (abstract no 703)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002366"
        }, 
        "source": "Abbott", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {
        "Prince Henry's Hosp / Med Oncology": "-33.874 151.207", 
        "Saint Vincent's Hosp Med Centre": "-33.874 151.207"
    }
}